ArticleFrontiers in pharmacology2018

Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells.

Wei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.